双歧杆菌三联活菌胶囊联合雷贝拉唑四联疗法治疗对幽门螺杆菌阳性慢性浅表性胃炎患者临床疗效的影响  

Impact of Bifidobacterium Triple Viable Capsules Combined with Rabeprazole Quadruple Therapy on the Clinical Efficacy in Patients with Helicobacter Pylori-Positive Chronic Superficial Gastritis

作　　者：周学媛 ZHOU Xueyuan(Department of Spleen and Stomach Diseases,Yantai Penglai Hospital of Traditional Chinese Medicine,Yantai 265600,China)

机构地区：[1]烟台市蓬莱中医医院脾胃病科,山东烟台265600

出　　处：《反射疗法与康复医学》2024年第23期153-156,共4页Reflexology And Rehabilitation Medicine

摘　　要：目的探讨双歧杆菌三联活菌胶囊联合雷贝拉唑四联疗法对幽门螺杆菌(Hp)阳性慢性浅表性胃炎(CSG)患者的作用。方法选取2022年4月—2024年6月烟台市蓬莱中医医院收治的84例Hp阳性CSG患者为研究对象,按随机数字表法将其分为对照组和观察组,每组42例。对照组采用雷贝拉唑四联疗法治疗,观察组在对照组基础上采用双歧杆菌三联活菌胶囊治疗,两组患者均持续治疗14 d。比较两组的临床疗效、Hp根除率、胃肠激素水平、不良反应发生情况。结果观察组治疗总有效率为95.24%,高于对照组的80.95%,差异有统计学意义(P<0.05)。观察组的根除率为92.86%,高于对照组的76.19%,差异有统计学意义(P<0.05)。治疗前,两组胃肠激素水平比较,差异无统计学意义(P>0.05);治疗后,两组胃动力素、生长抑素水平均高于治疗前,且观察组均高于对照组,两组血清胃泌素水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论双歧杆菌三联活菌胶囊联合雷贝拉唑四联疗法应用于Hp阳性CSG患者中,可增强疗效,能够有效根除Hp,改善胃肠激素水平,且不良反应少。Objective To explore the effect of bifidobacterium triple viable capsules combined with rabeprazole quadruple therapy on patients with Helicobacter pylori(Hp)-positive chronic superficial gastritis(CSG).Methods Eighty-Four patients with Hp-positive CSG who were admitted to Yantai Penglai Hospital of Traditional Chinese Medicine from April 2022 to June 2024 were selected as the research objects.They were divided into a control group and an observation group according to the random number table method,with 42 cases in each group.The control group was treated with rabeprazole quadruple therapy,while the observation group was treated with bifidobacterium triple viable capsules on the basis of the control group,both groups of patients received continuous treatment for 14 days.The clinical efficacy,Hp eradication rate,gastrointestinal hormone levels and the occurrence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.24%,which was higher than 80.95%of the control group,and the difference was statistically significant(P<0.05).The eradication rate in the observation group was 92.86%,which was higher than 76.19%in the control group,and the difference was statistically significant(P<0.05).Before treatment,the comparison of gastrointestinal hormone levels between the two groups,and the difference was not statistically significant(P>0.05);after treatment,the levels of motilin and somatostatin in both groups were higher than those before treatment,and the levels in the observation group were higher than those in the control group,the levels of serum gastrin in both groups were lower than those before treatment,and the level in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Comparison of the incidence rates of adverse reactions between the two groups,and the difference was not statistically significant(P>0.05).Conclusion The bifidobacterium triple viable capsules combine

关 键 词：慢性浅表性胃炎 HP阳性 双歧杆菌三联活菌胶囊 雷贝拉唑四联疗法 胃肠激素 

分 类 号：R573.31[医药卫生—消化系统]